Industry News Archive

  • FDA Approves Pembrolizumab for First-line Treatment of Metastatic MSI-H or dMMR CRC

    On June 29, 2020, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co.) for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

    Read FDA announcement.

    Posted 6/30/2020



  • Live Discussion: CD38-Directed Antibody for the Treatment of RRMM

    CD38-Directed Antibody for the Treatment of Appropriate Relapsed Refractory Multiple Myeloma Patients
     
    Thursday, June 25
    5:00 PM PT

    Participants of this live discussion will be able to:

    • Learn about the indication, mechanism of action, and important safety information for Sarclisa (isatuximab-irfc)

    • Gain in-depth knowledge on clinical data in adult patients with relapsed refractory multiple myeloma

    • Understand the dosage and administration of Sarclisa.

    • Learn about support available for eligible patients treated with Sarclisa. 

    For registration information or to learn more, click here

    Posted 6/25/2020



  • Astellas and Seattle Genetics Issue Product-Specific J-code for PADCEV

    Astellas and Seattle Genetics are pleased to announce the assignment of a product-specific, permanent J-code for PADCEV. CMS released the July 2020 Quarterly Healthcare Common Procedural Coding System File, which includes the designation of J9177 for PADCEV with the effective date of July 1, 2020. 

    Read corporate announcement.

    Posted 6/25/20



  • FDA Approves Pembrolizumab for Recurrent or Metastatic cSCC

    On June 24, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck & Co., Inc.) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

    Read the FDA announcement.

    Posted 6/24/2020



  • ELITEK Pivotal Trial Overview

    ELITEK (Sanofi-Genzyme) is indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ELITEK is indicated only for a single course of treatment.

    Read pivotal trial overview.

    Posted 6/22/2020



  • Taiho Oncology Patient Support Program

    Taiho Oncology Patient Support offers personalized services to give patients, caregivers, and healthcare professionals the help they need in getting started with Taiho Oncology Products. This includes insurance verification, help with medication costs, and treatment plan support.

    Learn more

    Posted 6/22/2020



  • Lonsurf Efficacy Flashcard

    Lonsurf®  (FTD/TPI, Taiho Oncology) is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.


    Read efficacy and safety information

    Posted 6/22/2020



  • Sanofi Introduces the Libtayo Surround Online Portal

    Healthcare providers can now help patients enroll in LIBTAYO Surround online portal.

    Click here for more information.

    Posted 6/22/2020



  • FDA Approves Tabrecta for Metastatic NSCLC with METex14

    On May 6, 2020, Novartis announced that the U.S. Food and Drug Administration (FDA) approved TabrectaTM (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

    Read corporate press release

    Posted 6/22/2020



  • Pfizer Oncology Personalized Support

    At Pfizer Oncology Together, patient support is at the core of everything they do. From helping to identify financial assistance options to connecting patients to resources for emotional support, the needs of patients prescribed Pfizer Oncology medications are a top priority.

    Pfizer Oncology Field Reimbursement Managers (FRMs) can help address challenging or urgent Pfizer Oncology patient access cases. Click here for the FRM contact in Tennessee.

    Posted 6/22/2020




1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
tops-tennessee.com
Email Us